Heart Rate Variability modifications induced by high doses of incobotulinumtoxinA and onabotulinumtoxinA in hemiplegic chronic stroke patients: A single blind randomized controlled, crossover pilot study.

Details

Ressource 1Request a copy Sous embargo indéterminé.
State: Public
Version: Final published version
License: Not specified
Serval ID
serval:BIB_5897E72D286D
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Heart Rate Variability modifications induced by high doses of incobotulinumtoxinA and onabotulinumtoxinA in hemiplegic chronic stroke patients: A single blind randomized controlled, crossover pilot study.
Journal
Toxicon
Author(s)
Baricich A., Grana E., Carda S., Santamato A., Molinari C., Cisari C., Invernizzi M.
ISSN
1879-3150 (Electronic)
ISSN-L
0041-0101
Publication state
Published
Issued date
11/2017
Peer-reviewed
Oui
Volume
138
Pages
145-150
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Botulinum toxin type A is a valid and safe treatment for focal spasticity, with documented effects on both sympathetic and parasympathetic systems. Heart rate variability can provide detailed information about the control of the autonomic nervous system on cardiovascular activities. Previous studies in literature showed no significant changes in Heart Rate Variability with doses >600 U of incobotulinumtoxinA in chronic post stroke spastic patients; however, at present time, these results have not been confirmed with doses >600 U of onabotulinumtoxinA.
To evaluate changes in Heart Rate Variability induced by high doses (>600 U) of incobotulinumtoxinA or onabotulinumtoxinA in spastic stroke patients over a 1-year period.
single blind randomized controlled crossover study design.
Rehabilitation Unit of the University Hospital in Novara.
10 stroke survivors with spastic hemiplegia (Modified Ashworth Scale ≥ 2) were recruited and randomly divided in two groups (A and B).
In the first part of the study, patients in Group A were injected with incobotulinumtoxinA while patients in Group B with onabotulinumtoxinA; after 6 months, a crossover intervention was performed. All patients were blinded to Botulinum toxin type A type, and performed an ECG registration in the 24 h before injection (t0) and 10 days after treatment (t1), both in the first and in the second part of the study. Functional status was evaluated with Barthel Index, Motricity Index and Functional Ambulation Category scores.
Heart Rate Variability analysis showed no significant changes after each Botulinum toxin type A injection in both groups at any evaluation time. Moreover, no statistically significant differences were found regarding each variable between the two groups.
Our data show that high doses (>600 U) of incobotulinumtoxinA and onabotulinumtoxinA do not influence the cardiovascular activity of the autonomic nervous system in chronic hemiplegic spastic stroke survivors.
Keywords
Botulinum toxins, Heart rate, Muscle spasticity, Stroke, Type A
Pubmed
Create date
07/09/2017 13:36
Last modification date
15/07/2020 6:22
Usage data